Rozprawy doktorskie na temat „Marophase Colony Stimulating Factors”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 36 najlepszych rozpraw doktorskich naukowych na temat „Marophase Colony Stimulating Factors”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj rozprawy doktorskie z różnych dziedzin i twórz odpowiednie bibliografie.
Mohamad, Anuar Nur Najmi. "Regulation of vascular cells function by colony stimulating factors". Thesis, University of Bristol, 2016. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.702911.
Pełny tekst źródłaKu, Chun-Ying. "Colony-Stimulating Factor from Umbilical Cord Endothelial Cells". Thesis, North Texas State University, 1987. https://digital.library.unt.edu/ark:/67531/metadc935638/.
Pełny tekst źródłaKu, Chun-Ying. "Regulation of Colony-Stimulating Factor-1 Biosynthesis". Thesis, University of North Texas, 1990. https://digital.library.unt.edu/ark:/67531/metadc332103/.
Pełny tekst źródłaLiu, Mu-ya. "Induced CSF-1 Production and its Effects on C-FMS Transfected Monoblastic U937 Cells". Thesis, University of North Texas, 1992. https://digital.library.unt.edu/ark:/67531/metadc798317/.
Pełny tekst źródłaTazi, Abdellatif. "Les colony-stimulating factors dans les réponses immunitaires et inflammatoires pulmonaires". Paris 5, 1993. http://www.theses.fr/1993PA05CD02.
Pełny tekst źródłaHercus, Timothy Robert. "Structure-junction studies on human granulocyte-macrophage colony-stimulating factor /". Title page, table of contents and summary only, 1994. http://web4.library.adelaide.edu.au/theses/09PH/09phh539.pdf.
Pełny tekst źródłaShieh, Jae-Hung. "Purification, Characterization and Receptor Binding of Human Colony-Stimulating Factor-1". Thesis, North Texas State University, 1987. https://digital.library.unt.edu/ark:/67531/metadc331991/.
Pełny tekst źródłaTowers, Terri L. "Vitamin D3-mediated transcriptional repression : of the granulocyte-macrophage colony stimulating factor gene /". Access full-text from WCMC, 1998. http://proquest.umi.com/pqdweb?did=733066141&sid=3&Fmt=2&clientId=8424&RQT=309&VName=PQD.
Pełny tekst źródłaOlivares, Fontt Elizabeth. "Rôle du granolocyte-macrophage colony-stimulating factors lors de l'infection expérimentale à Trypanosoma cruzi". Doctoral thesis, Universite Libre de Bruxelles, 1995. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/212546.
Pełny tekst źródłaElliott, Michael J. H. "The interactions of interleukin-3 and granulocyte-macrophage colony-stimulating factor with human monocytes /". Title page, table of contents and abstract only, 1989. http://web4.library.adelaide.edu.au/theses/09PH/09phe464.pdf.
Pełny tekst źródłaChiou, Chuang-Jiun. "Expression of Granulocyte-Macrophage Colony-Stimulating Factor Gene in Insect Cells by a Baculovirus Vector". Thesis, University of North Texas, 1989. https://digital.library.unt.edu/ark:/67531/metadc798471/.
Pełny tekst źródłaLiu, Hebin. "RUNX1/AML1 functions and mechanisms regulating granulocyte-macrophage colony-stimulating factor transcription". Doctoral thesis, Umeå : Department of Molecular Biology, Umeå University, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-486.
Pełny tekst źródłaStanford, Salome Jane. "Role of colony-stimulating factors synthesised by human vascular smooth muscle in the regulation of neutrophil survival". Thesis, Imperial College London, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.341915.
Pełny tekst źródłaBernstone, Laura. "Characterisation of HIV-1 infection and M-CSF and GM-CSF macrophages". Thesis, University of Oxford, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.572833.
Pełny tekst źródłaRahmati, Mona. "Granulocyte-Colony Stimulating Factor and Embryo Implantation Process : Effects on Human Endometrium and on Murine Abortion Prone Model CBA/J x DBA/2". Thesis, Paris 11, 2014. http://www.theses.fr/2014PA11T048/document.
Pełny tekst źródłaReproductive Immunology involves general immunology principles and special aspects of reproduction and development. Colony Stimulating Factors (CSFs) are an illustration of the medical application of this domain. In the CSF family, Granulocyte-Colony Stimulating Factor (G-CSF) appears today as a promising therapy in various cases of reproductive failure although its targets and effects are not clearly established. In this work, through a review on CSFs in reproduction, a study dedicated to human endometrial targets of G-CSF, and a study dedicated to systemic G-CSF supplementation effects on murine embryo implantation, we tried to approach some possible mechanisms of action of this cytokine. In the considered non-abortive and abortion-prone murine models, the timed systemic G-CSF supplementation, targeting specifically the pre implantation endometrium, influenced the embryo implantation process. Some pre conceptual human endometrial dysregulations of G-CSF target genes were also observed in infertile patients. The endometrial influence of G-CSF on these target genes was also illustrated in an ex-vivo model. These molecules under G-CSF influence are described as critically involved in embryo implantation process, by influencing embryo adhesion, cell migration, tissue remodelling and angiogenesis. These data suggest possible pre-conceptual preventive diagnosis of such reproductive failures and future orientated therapies to optimise the endometrial biosensor and the further embryo implantation and ongoing pregnancy
Robertson, Sarah A. "Granulocyte-macrophage colony stimulating factor (GM-CSF) : a paracrine regulator in the pre-implantation mouse uterus". Title page, abstract and contents only, 1993. http://web4.library.adelaide.edu.au/theses/09PH/09phr6515.pdf.
Pełny tekst źródłaStöcker, Kai [Verfasser], i Wolf-Rüdiger [Akademischer Betreuer] Schäbitz. "Effekte des Granulocyte-Colony-Stimulating-Factors (G-CSF) nach Schlaganfall bei alten Ratten / Kai Stöcker. Betreuer: Wolf-Rüdiger Schäbitz". Münster : Universitäts- und Landesbibliothek der Westfälischen Wilhelms-Universität, 2012. http://d-nb.info/1027018777/34.
Pełny tekst źródłaBOUCHER, ARSENTA VALERIE. "Utilisation des facteurs de croissance granulocytaire dans les agranulocytoses medicamenteuses". Nice, 1994. http://www.theses.fr/1994NICE6546.
Pełny tekst źródłaGeary, Sean Michael. "Manipulation of the immunostimulatory capacity of a human myeloid leukaemia cell line HL-60 /". Title page, contents and abstract only, 1993. http://web4.library.adelaide.edu.au/theses/09PH/09phg292.pdf.
Pełny tekst źródłaOsborne, Cameron Stuart. "Transcriptional regulation of the GM-CSF gene in T lymphocytes /". Title page, contents and summary only, 1996. http://web4.library.adelaide.edu.au/theses/09PH/09pho81.pdf.
Pełny tekst źródłaViolante, Ana Cristina Martins da. "Contribuição para o estudo da utilização de fatores estimuladores de colónias de granulócitos no maneio de doenças associadas a neutropénia em cães e gatos : estudo retrospetivo de 30 casos clínicos (2011 – 2016)". Master's thesis, Universidade de Lisboa, Faculdade de Medicina Veterinária, 2016. http://hdl.handle.net/10400.5/12721.
Pełny tekst źródłaA neutropénia é um achado hematológico que se encontra associado a várias afeções no cão e no gato e, ao ser responsável pelo estabelecimento de um estado de imunossupressão, contribui de modo significativo para o agravamento da morbilidade e mortalidade dos doentes. No sentido de reverter a neutropénia e prevenir as suas consequências, podem ser administrados fatores estimuladores de colónias de granulócitos recombinantes humanos (rhG-CSF) que aceleram a produção e diferenciação dos neutrófilos na medula óssea e causam a sua saída para o sangue. Assim, esta dissertação teve como objetivo avaliar retrospetivamente a utilização de rhG-CSF em várias doenças em canídeos e felídeos, de modo a contribuir para um maior conhecimento do seu uso em medicina veterinária. Neste estudo, os rhG-CSF foram administrados a animais com neutropénia induzida pela infeção por parvovírus canino e felino (60,0%), por fármacos citotóxicos (20,0%) e hipoplasia da medula óssea (20,0%). A maioria destes animais apresentou-se com neutropénia grave (46,7%), seguida de neutropénia moderada (33,3%) e ligeira (20,0%). A utilização dos rhG-CSF foi avaliada através de hemogramas realizados antes da primeira administração e após 48 horas. Em todos os grupos foram encontrados aumentos significativos nas contagens absolutas dos leucócitos totais e neutrófilos. No grupo amostral de animais com infeção por parvovírus foi também observado um aumento significativo no número de monócitos, linfócitos e eosinófilos. Uma diminuição na contagem dos eritrócitos foi ainda encontrada no grupo de animais com infeção por parvovírus e mielotoxicidade secundária a fármacos citotóxicos, mas o seu significado é questionável. Como segunda parte deste estudo foi feita uma análise individual dos casos clínicos, na qual se verificou que a taxa de resposta aos rhG-CSF foi de 73,3%. Para além disto, foi ainda investigada a existência de associação entre a taxa de resposta e outras variáveis registadas, tendo-se encontrado uma associação com a etiologia (p = 0,041) e o desfecho clínico, classificado como alta médica ou óbito (p = 0,001). Apesar do pequeno tamanho da amostra estudada, os resultados da presente dissertação sugerem que a utilização de rhG-CSF em cães e gatos apresenta efeitos terapêuticos benéficos a nível hematológico, sendo bem tolerados quando administrados em protocolos de curta duração.
ABSTRACT - Contribution to the study of the use of granulocyte colony-stimulating factors in the management of diseases associated with neutropenia in dogs and cats: retrospective study of 30 clinical cases (2011 – 2016) - Neutropenia is a hematological finding that can be caused by a diversity of diseases in dogs and cats and, by being responsible for an immunocompromised state, contributes significantly to patient morbidity and mortality. In order to reverse neutropenia and prevent its consequences, human recombinant granulocyte colony-stimulating factors (rhG-CSF) can be used, which are drugs that increase neutrophil production and differentiation in the bone marrow and their release into the blood. The aim of this dissertation was to retrospectively evaluate the use of rhG-CSF in various clinical conditions in canine and feline patients, contributing to a greater knowledge of their use in veterinary medicine. In this study rhG-CSF were administrated to animals with neutropenia induced by canine and feline parvovirus infection (60,0%), by cytotoxic drugs (20,0%) and bone marrow hypoplasia (20,0%). The majority of these animals presented with severe neutropenia (46,7%), followed by moderate (33,3%) and mild neutropenia (20,0%). The use of these drugs was evaluated through complete blood counts performed before the first administration and after 48 hours. In all groups significant increases on total leukocyte and neutrophil counts were observed. In the sample group of animals with parvovirus infection a significant increase in the number of monocytes, lymphocytes and eosinophils was also found. A decrease in the number of erythrocytes was also seen in the group of animals with parvovirus infection and myelotoxicity secondary to cytotoxic drugs, but its meaning is questionable. As a second part of this study, an individual analysis of the clinical cases was made, which showed that the overall response rate to rhG-CSF was 73,3%. Moreover, associations between the response rate and other variables were investigated and it was encountered an association with etiology (p = 0,041) and clinical outcome, classified as hospital discharge or patient death (p = 0,001). Despite the small sample size, the results of the present dissertation suggest that the use of rhG-CSF in dogs and cats brings beneficial therapeutic effects on a hematological level and are well tolerated when administered in short protocols.
N/A
Tehranchi, Ramin. "Apoptosis in myelodysplastic syndromes : effects of hemopoietic growth factors /". Stockholm, 2004. http://diss.kib.ki.se/2004/91-7140-045-1/.
Pełny tekst źródłaLiutkauskienė, Sigita. "P53 baltymo raiškos ir kitų veiksnių prognozinės vertės tyrimas, gydant krūties vėžį chemoterapija ir granuliocitų kolonijas stimuliuojančiais faktoriais". Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2010. http://vddb.laba.lt/obj/LT-eLABa-0001:E.02~2010~D_20101122_113300-78280.
Pełny tekst źródłaThis study investigated the clinical outcomes in early and metastatic breast cancer patients depending on chemotherapy and molecular markers. The study comprised of 3 parts: Part I - retrospective investigation of molecular markers (p53 protein, HER2 receptors, estrogene and progesterone receptors) and chemotherapy dose reduction in early stage breast cancer; Part II - prospective open-label multicenter phase IV clinical trial on safety and effectiveness of GCSF used in chemotherapy of metastatic breast cancer; Part III - investigation of prognostic value of p53 protein expression and other molecular markers in metastatic breast cancer when optimal chemotherapy dose was adjusted in prospective multicenter trial of new rGCSF on safety and effectiveness used in chemotherapy of metastatic breast cancer. Objectives: 1. To establish the influence of anthracycline dose on survival of early stage breast cancer patients. 2. To evaluate the influence of p53 protein expression and other molecular markers as well as treatment on prognosis of early stage breast cancer. 3. To establish the safety of new rGCSF prescribed for prevention of febrile neutropenia in chemotherapy of metastatic breast cancer. 4. To analyze the effectiveness of new rGCSF prescribed for prevention of febrile neutropenia in chemotherapy of metastatic breast cancer. 5. To establish the relationship between response to treatment and survival in metastatic breast cancer patients. 6. To evaluate the associations among... [to full text]
Rafei, Moutih. "Fusokine design as novel therapeutic strategy for immunosuppression". Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=115882.
Pełny tekst źródłaAlong those lines, we also found that mesenchymal stromal cells (MSCs) lead to the paracrine conversion of CCL2 to an antagonist form capable of specifically inhibiting plasma cells and activated Th17 cells. This mechanistic insight informed the design of a second class of suppression fusokine. Namely, the fusing of antagonist CCL2 to GMCSF - aka GMME1. We tested its potential use in autoimmune diseases such as EAE and rheumatoid arthritis (RA). We demonstrated that GMME1 leads to asymmetrical signalling and inhibition of plasma cells as well as Th17 EAE/RA-reactive CD4 T-cells. The net outcome of these pharmacological effects is the selective depletion of CCR2-reactive T-cells as demonstrated both in vitro and in vivo.
Overall, our data support the use of our fusion proteins as part of a powerful and specific immunosuppressive strategy either as directly injectable protein biopharmaceuticals or through the ex vivo generation of autologous Bregs in the case of GIFT15.
Mamatha, B. N. "Proteomics-based Identification of Serum Biomarkers : Role of Secreted MCSF and CRP in Glioma Pathogenesis". Thesis, 2015. https://etd.iisc.ac.in/handle/2005/4810.
Pełny tekst źródłaElliott, Michael J. H. "The interactions of interleukin-3 and granulocyte-macrophage colony-stimulating factor with human monocytes / Michael J.H. Elliott". Thesis, 1989. http://hdl.handle.net/2440/19108.
Pełny tekst źródłaLee, Mei-Hsuan, i 李美萱. "The Role of Granulocyte-Macrophage Colony-Stimulating Factors (GM-CSF) in Galectin-3-Mediated Tumorigenesis". Thesis, 2016. http://ndltd.ncl.edu.tw/handle/75249965323079942811.
Pełny tekst źródłaLee, Wen-Hsun, i 李玟勳. "Risk of Developing Venous Thromboembolism Associated with Granulocyte-Colony Stimulating Factors (G-CSF) in Colorectal Cancer Patients". Thesis, 2016. http://ndltd.ncl.edu.tw/handle/19978293377271706067.
Pełny tekst źródła高雄醫學大學
藥學系碩士在職專班
104
Background: Chemotherapy (CT) is an effective treatment for increasing survival rates in various cancer patients. Usually, the bone marrow suppressive effect of CT may also cause severe febrile neutropenia, and granulocyte colony-stimulating factor (G-CSF) is often used for reducing the risk, severity, and duration of febrile neutropenia. However, some studies reported that G-CSF may also be associated with venous thromboembolism (VTE) in patients with cancer. Colorectal cancer is ranked the 3rd cancer death in Taiwan, and the association between G-CSF and VTE has not yet been investigated. Objective: To investigate whether the use of G-CSF in colorectal cancer (CRC) patients who received CT is associated with an increased risk of VTE. Methods: We conducted a retrospective cohort study using National Health Insurance Research Database (NHIRD) from 2002 to 2012. Patients who were diagnosed with CRC in 2003-2011 and received CT within 1 year after CRC diagnosis were included. We excluded patients who (1) were diagnosed with cancer within 1 year before the date of colorectal cancer diagnosis, (2) died within 1 year of colorectal cancer diagnosis, or were > 90 years old, (3) were diagnosed with VTE within 1 year before the first date of receiving CT, or before the date of receiving G-CSF, (4) received G-CSF within 1 year before the date of receiving CT, or received G-CSF without receiving CT. The remaining patients were further classified into two groups: (1) non-users of G-CSF (as reference group), (2) users of G-CSF. Patients were also divided into subgroups according to the status of receiving surgery or radiation therapy. Cox proportional hazards models were performed to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CI). Results: Among 41,736 eligible patients, there were more men (n =23,837, 57.11%) then women, and the average age was 62.76 (± 13.01) years old. 39,345 patients were non-users of G-CSF (94.27%), only 2,391 (5.73%) patients received G-CSF. The risk of VTE was not significantly different between users and non-users of G-CSF (HR 1.02, 95% CI 0.95-1.10). Among 30,510 (73.10%) patients who received surgery, similar HR was observed between users and non-users of G-CSF (HR 1.05, 95% CI 0.97-1.13). Among 11,226 (26.90%) patients without surgery, the HR became less than 1.0 (HR 0.96, 95% CI 0.84-1.11). Among 6,663 (15.96%) patients who received radiation therapy, the HR of VTE in users of G-CSF was 0.97 (HR 0.97, 95%CI 0.82-1.16), compared to non-users. Among 35,073 (84.04%) patients without radiation therapy, the HR of VTE was 1.03 (HR 1.03, 95%CI 0.96-1.12). However, all analyses of subgroups still revealed null effects. Conclusion: The risk for developing VTE was not significantly different between users and non-users of G-CSF in colorectal cancer patients who received CT. Patients with high-risk for developing VTE, the use of G-CSF should be reserved for patients for whom the benefits outweigh the risks.
Huang, Ya-Ching, i 黃雅菁. "Cloning and Expression of Porcine Granulocyte/Macrophage Colony- Stimulating Factors (GM-CSF) by Chinese Hamster Ovary (CHO) Cells". Thesis, 2006. http://ndltd.ncl.edu.tw/handle/04956550900552191903.
Pełny tekst źródłaXing-LuJiang i 姜幸呂. "Utilization of the Granulocyte Colony-stimulating Factors (G-CSF) for Managing Chemotherapy-induced Neutropenia in Breast Cancer Patients". Thesis, 2011. http://ndltd.ncl.edu.tw/handle/21087784198942209781.
Pełny tekst źródłaZhang, Yuan Heidi. "Mass spectrometric analysis of proteins and peptides : elucidation of the folding pathways of recombinant human macrophage colony stimulating factor beta". Thesis, 2002. http://hdl.handle.net/1957/37223.
Pełny tekst źródłaGraduation date: 2003
Geary, Sean Michael. "Manipulation of the immunostimulatory capacity of a human myeloid leukaemia cell line HL-60 / by Sean Michael Geary". Thesis, 1993. http://hdl.handle.net/2440/21505.
Pełny tekst źródłaBibliography: leaves 140-211.
211, [200] leaves, [12] leaves of plates : ill. (some col.) ; 30 cm.
Aims to determine the reason for the lack of ability of many myeloid leukaemic cell populations to stimulate allogeneic lymphocytes in mixed leucocyte culture (MLC), with a view to manipulating the immunogenicity of these cells for therapeutic purposes.
Thesis (Ph.D.)--University of Adelaide, Dept. of Microbiology and Immunology, 1995
Osborne, Cameron Stuart. "Transcriptional regulation of the GM-CSF gene in T lymphocytes / Cameron Stuart Osborne". Thesis, 1996. http://hdl.handle.net/2440/18868.
Pełny tekst źródłaIncludes bibliographies.
109, [99] leaves, [5] leaves of plates : ill. ; 30 cm.
Describes the investigation as to whether the mouse granulocyte-macrophage colony-stimulating factor and interleukin-3 genes are regulated in a similar manner as those of the human, focussing on regulation through an enhancer.
Thesis (Ph.D.)--University of Adelaide, Dept. of Microbiology and Immunology, 1996
Shirvaikar, Neeta Chandan. "Role of membrane-type 1 matrix metalloproteinase in hematopoietic stem/progenitor cell trafficking". Phd thesis, 2010. http://hdl.handle.net/10048/1146.
Pełny tekst źródłaA thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Doctor of Philosophy, Medicine. Title from pdf file main screen (viewed on April 27, 2010). Includes bibliographical references.
Byts, Nadiya. "Signalling of hematopoietic growth factors in mammalian neural cells". Doctoral thesis, 2007. http://hdl.handle.net/11858/00-1735-0000-0006-B36E-9.
Pełny tekst źródłaPham, Duy. "Twist1 and Etv5 are part of a transcription factor network defining T helper cell identity". Thesis, 2014. http://hdl.handle.net/1805/4657.
Pełny tekst źródłaCD4 T helper cells control immunity to pathogens and the development of inflammatory disease by acquiring the ability to secrete effector cytokines. Cytokine responsiveness is a critical component of the ability of cells to respond to the extracellular milieu by activating Signal Transducer and Activator of Transcription factors that induce the expression of other transcription factors important for cytokine production. STAT4 is a critical regulator of Th1 differentiation and inflammatory disease that attenuates the gene-repressing activity of Dnmt3a. In the absence of STAT4, genetic loss of Dnmt3a results in de-repression of a subset of Th1 genes, and a partial increase in expression that is sufficient to observe a modest recovery of STAT4-dependent inflammatory disease. STAT4 also induces expression of the transcription factors Twist1 and Etv5. We demonstrate that Twist1 negatively regulates Th1 cell differentiation through several mechanisms including physical interaction with Runx3 and impairing STAT4 activation. Following induction by STAT3-activating cytokines including IL-6, Twist1 represses Th17 and Tfh differentiation by directly binding to, and suppressing expression of, the Il6ra locus, subsequently reducing STAT3 activation. In contrast, Etv5 contributes only modestly to Th1 development but promotes Th differentiation by directly activating cytokine production in Th9 and Th17 cells, and Bcl6 expression in Tfh cells. Thus, the transcription factors Twist1 and Etv5 provide unique regulation of T helper cell identity, ultimately impacting the development of cell-mediated and humoral immunity.